drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor targeting CD19-positive B-cell malignancies, mediating TCR-independent activation, cytokine release, cytotoxicity, and in vivo expansion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express an anti-CD19 chimeric antigen receptor. Upon binding CD19 on malignant B cells, the CAR provides TCR/MHC-independent activation signals that trigger T-cell activation, cytokine release, proliferation, and cytotoxic killing of CD19-positive tumor cells.
drug_name
Commercial CD19 CAR-T (China)
nct_id_drug_ref
NCT06049381